NYSE:BHVN Biohaven (BHVN) Stock Price, News & Analysis → Your Money is Not Safe (From American Alternative) (Ad) Free BHVN Stock Alerts $54.69 -2.33 (-4.09%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$54.65▼$57.0250-Day Range$43.69▼$59.7452-Week Range$12.35▼$62.21Volume841,086 shsAverage Volume1.74 million shsMarket Capitalization$4.46 billionP/E RatioN/ADividend YieldN/APrice Target$49.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Biohaven alerts: Email Address Biohaven MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside9.2% Downside$49.67 Price TargetShort InterestBearish10.58% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.03Based on 6 Articles This WeekInsider TradingSelling Shares$459,690 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.85) to ($5.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.68 out of 5 starsMedical Sector723rd out of 939 stocksPharmaceutical Preparations Industry344th out of 444 stocks 2.5 Analyst's Opinion Consensus RatingBiohaven has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $49.67, Biohaven has a forecasted downside of 9.2% from its current price of $54.69.Amount of Analyst CoverageBiohaven has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.58% of the outstanding shares of Biohaven have been sold short.Short Interest Ratio / Days to CoverBiohaven has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Biohaven has recently increased by 11.64%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBiohaven does not currently pay a dividend.Dividend GrowthBiohaven does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BHVN. Previous Next 3.9 News and Social Media Coverage News SentimentBiohaven has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Biohaven this week, compared to 3 articles on an average week.Search Interest34 people have searched for BHVN on MarketBeat in the last 30 days. This is an increase of 240% compared to the previous 30 days.MarketBeat Follows16 people have added Biohaven to their MarketBeat watchlist in the last 30 days. This is an increase of 78% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biohaven insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $459,690.00 in company stock.Percentage Held by Insiders16.00% of the stock of Biohaven is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.78% of the stock of Biohaven is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biohaven are expected to grow in the coming year, from ($5.85) to ($5.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biohaven is -9.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biohaven is -9.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiohaven has a P/B Ratio of 10.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad American AlternativeYour Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…CLICK HERE TO GET YOUR GUIDE NOW About Biohaven Stock (NYSE:BHVN)Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Read More BHVN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BHVN Stock News HeadlinesMarch 27, 2024 | msn.comObesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli LillyMarch 27, 2024 | americanbankingnews.comBiohaven Ltd. (NYSE:BHVN) Receives Consensus Recommendation of "Buy" from AnalystsMarch 29, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…March 20, 2024 | finance.yahoo.comBullish Biohaven Insiders Loaded Up On US$23.8m Of StockMarch 13, 2024 | finance.yahoo.comBHVN Apr 2024 80.000 callMarch 13, 2024 | finance.yahoo.comBHVN Oct 2024 90.000 callMarch 13, 2024 | finance.yahoo.comBHVN May 2024 70.000 callMarch 12, 2024 | finance.yahoo.comBHVN Apr 2024 45.000 putMarch 29, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…March 12, 2024 | finance.yahoo.comBHVN Oct 2024 30.000 callMarch 7, 2024 | nasdaq.comInteresting BHVN Put And Call Options For May 17thMarch 5, 2024 | markets.businessinsider.comBuy Rating Affirmed: Biohaven’s Innovative Pipeline and Financial Health Signal Promising FutureMarch 4, 2024 | markets.businessinsider.comBuy Rating Affirmed: Biohaven Ltd. Poised for Key Milestones with Diverse Portfolio and Promising Lead Molecule BHV-7000March 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for Biohaven Ltd. on Strong Pipeline and Upcoming Drug AdvancementsMarch 1, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Veeva Systems (VEEV), Xenon (XENE)March 1, 2024 | realmoney.thestreet.comBiohaven price target raised by $20 at TD Cowen, here's whyFebruary 29, 2024 | prnewswire.comBiohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business DevelopmentsFebruary 28, 2024 | seekingalpha.comBiohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)February 27, 2024 | morningstar.comBiohaven Ltd BHVNFebruary 24, 2024 | msn.comBiohaven (BHVN) Price Target Increased by 29.07% to 56.61February 20, 2024 | ca.finance.yahoo.comBHVN Mar 2024 30.000 putFebruary 19, 2024 | ca.finance.yahoo.comBHVN Mar 2024 50.000 callFebruary 19, 2024 | ca.finance.yahoo.comBHVN Oct 2024 70.000 callFebruary 19, 2024 | msn.comArsenal suffer Pedro Neto transfer blow after Wolves forward stars at TottenhamFebruary 18, 2024 | finance.yahoo.comA Look At The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)February 16, 2024 | msn.comThis Analyst Is Bullish On Biohaven's Approach in Neuro-Psych SpaceFebruary 16, 2024 | msn.comRBC Capital starts Biohaven at outperform, cites epilepsy drugSee More Headlines Receive BHVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today3/29/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:BHVN Previous SymbolNASDAQ:BHVN CUSIPN/A CIK1689813 Webwww.biohavenpharma.com Phone203-404-0410FaxN/AEmployees239Year FoundedN/APrice Target and Rating Average Stock Price Target$49.67 High Stock Price Target$63.00 Low Stock Price Target$28.00 Potential Upside/Downside-9.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($5.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-408,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-103.50% Return on Assets-80.78% Debt Debt-to-Equity RatioN/A Current Ratio7.98 Quick Ratio7.98 Sales & Book Value Annual Sales$462.51 million Price / Sales9.65 Cash FlowN/A Price / Cash FlowN/A Book Value$5.34 per share Price / Book10.24Miscellaneous Outstanding Shares81,600,000Free Float68,541,000Market Cap$4.46 billion OptionableOptionable Beta1.18 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Vladimir Coric M.D. (Age 53)Chairman & CEO Comp: $1.85MMr. Matthew Buten (Age 63)Chief Financial Officer Comp: $939.45kDr. Bruce D. Car DACVP (Age 62)Ph.D., Chief Scientific Officer Comp: $646.89kMs. Deb YoungDirector of Regulatory Affairs & OperationsMr. George C. Clark (Age 40)VP & Chief Accounting Officer Ms. Jennifer PorcelliVice President of Investor RelationsMr. Warren Volles J.D.General Counsel & Chief Legal OfficerMr. Clifford Bechtold M.S.President, GM of Biohaven Ireland & Chief Compliance OfficerMs. Kimberly Gentile (Age 58)Senior Vice President of Clinical Operations Mr. John Tilton (Age 56)Chief Commercial Officer of Rare Diseases More ExecutivesKey CompetitorsOrganon & Co.NYSE:OGNAlkermesNASDAQ:ALKSNuvalentNASDAQ:NUVLMadrigal PharmaceuticalsNASDAQ:MDGLPerrigoNYSE:PRGOView All CompetitorsInsiders & InstitutionsHealthcare of Ontario Pension Plan Trust FundBought 253,000 shares on 3/21/2024Ownership: 0.310%Vanguard Group Inc.Bought 229,168 shares on 3/11/2024Ownership: 2.033%Wellington Management Group LLPBought 13,866 shares on 3/5/2024Ownership: 0.017%Goldman Sachs Group Inc.Bought 71,850 shares on 3/1/2024Ownership: 1.179%American International Group Inc.Bought 4,922 shares on 2/28/2024Ownership: 0.042%View All Insider TransactionsView All Institutional Transactions BHVN Stock Analysis - Frequently Asked Questions Should I buy or sell Biohaven stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biohaven in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BHVN shares. View BHVN analyst ratings or view top-rated stocks. What is Biohaven's stock price target for 2024? 8 Wall Street research analysts have issued 1-year price targets for Biohaven's stock. Their BHVN share price targets range from $28.00 to $63.00. On average, they anticipate the company's stock price to reach $49.67 in the next year. This suggests that the stock has a possible downside of 9.2%. View analysts price targets for BHVN or view top-rated stocks among Wall Street analysts. How have BHVN shares performed in 2024? Biohaven's stock was trading at $42.80 at the start of the year. Since then, BHVN shares have increased by 27.8% and is now trading at $54.69. View the best growth stocks for 2024 here. Are investors shorting Biohaven? Biohaven saw a increase in short interest during the month of February. As of February 29th, there was short interest totaling 7,730,000 shares, an increase of 21.0% from the February 14th total of 6,390,000 shares. Based on an average trading volume of 1,130,000 shares, the short-interest ratio is currently 6.8 days. View Biohaven's Short Interest. When is Biohaven's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our BHVN earnings forecast. How were Biohaven's earnings last quarter? Biohaven Ltd. (NYSE:BHVN) posted its earnings results on Thursday, February, 29th. The company reported ($1.81) EPS for the quarter, missing the consensus estimate of ($1.41) by $0.40. What ETFs hold Biohaven's stock? ETFs with the largest weight of Biohaven (NYSE:BHVN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Invesco Dorsey Wright Healthcare Momentum ETF (PTH). What other stocks do shareholders of Biohaven own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT). When did Biohaven IPO? Biohaven (BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers. Who are Biohaven's major shareholders? Biohaven's stock is owned by many different retail and institutional investors. Top institutional shareholders include Stifel Financial Corp (7.76%), Price T Rowe Associates Inc. MD (3.91%), Price T Rowe Associates Inc. MD (3.91%), Point72 Asset Management L.P. (3.10%), Perceptive Advisors LLC (2.15%) and Vanguard Group Inc. (2.07%). Insiders that own company stock include Declan Doogan, Elyse Stock, George C Clark, Gregory Bailey, Irina Antonijevic, James Engelhart, John W Childs, Julia P Gregory, Matthew Buten and Vlad Coric. View institutional ownership trends. How do I buy shares of Biohaven? Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:BHVN) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaOnly a fool would buy Nvidia today… Porter & CompanyThe ONE AI Sock to own now. (It’s not Nvidia.)Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biohaven Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.